Navigation Links
Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
Date:4/10/2008

d circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12 and PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on U.S. EDGAR and in Canada on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncothyreon announces effectiveness of shelf registration statement
2. Oncothyreon announces issuance of patent for PX-867
3. Oncothyreon to present at upcoming investment conferences
4. Oncothyreon reports full year and fourth quarter 2007 financial results
5. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
6. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
7. Oncothyreon launches new corporate website
8. Oncothyreon to present at BIO CEO & Investor Conference
9. Oncothyreon highlights corporate and clinical objectives for 2008
10. Biomira announces plan to change name to Oncothyreon
11. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... Francisco, CA (PRWEB) April 30, 2015 Cytokinetics, ... the first quarter of 2015 were $4.4 million, compared to ... net loss for the first quarter was $8.9 million, or ... a net loss for the same period in 2014, of ... As of March 31, 2015, cash, cash equivalents and investments ...
(Date:4/30/2015)... 30, 2015 Biodata, producer of ... integrated protocols and specimen management systems, and ChemAxon, ... consulting services for life science research, announce their ... newest feature: chemical structure and reaction support. Already ... biologists, bio-chemists, and more, the integration of ChemAxon's ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Agence de Medecine,Preventive (AMP) announced today the appointment ... SIVAC (Supporting Independent Immunization and,Vaccine Advisory Committees) initiative. ... national immunization technical advisory groups in six,resource poor ... committees will help,national health authorities to set up ...
... 12 Synvista Therapeutics, Inc. (NYSE Alternext ... BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of ... the effect of alagebrium on exercise tolerance in patients with ... enrollment of its BREAK ( B eginning a R ...
... ANA, Calif., Jan. 12 ,Abbott ( NYSE: ABT ) and ... a definitive agreement for Abbott to acquire AMO for $22 ... $2.8 billion, inclusive,of estimated net debt at the time of ... leader in ophthalmic care, comprised of three segments: cataract,surgery, laser ...
Cached Biology Technology:French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... fossilized tracksite in southern Africa shows how early dinosaurs ... slippery and sloping terrain. Differences in how early dinosaurs ... of the group. The research, conducted by researchers ... Aires, and the Iziko South African Museum in Cape ...
... risk of allergy. Cathleen Muche-Borowski and her coauthors present ... current issue of Deutsches rzteblatt International (Dtsch ... becoming increasingly common in Western industrialized countries. As there ... hay fever, or atopic eczema, the prevention of these ...
... Va. A five-year-old Virginia Tech outreach program, ... doing research and providing results that scientists can ... Partnership Award from the National Center for Research ... of Health. The Fralin Life Science Institute,s Partnership ...
Cached Biology News:Trackway analysis shows how dinosaurs coped with slippery slopes 2Trackway analysis shows how dinosaurs coped with slippery slopes 3NIH funds new phase of high school-university research partnership 2NIH funds new phase of high school-university research partnership 3